226 related articles for article (PubMed ID: 15153938)
1. Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status.
Quist SR; Wang-Gohrke S; Köhler T; Kreienberg R; Runnebaum IB
Cancer Gene Ther; 2004 Aug; 11(8):547-54. PubMed ID: 15153938
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.
Wen SF; Xie L; McDonald M; DiGiacomo R; Chang A; Gurnani M; Shi B; Liu S; Indelicato SR; Hutchins B; Nielsen LL
Cancer Gene Ther; 2000 Nov; 7(11):1469-80. PubMed ID: 11129289
[TBL] [Abstract][Full Text] [Related]
3. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G
Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
[TBL] [Abstract][Full Text] [Related]
4. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.
Buller RE; Runnebaum IB; Karlan BY; Horowitz JA; Shahin M; Buekers T; Petrauskas S; Kreienberg R; Slamon D; Pegram M
Cancer Gene Ther; 2002 Jul; 9(7):553-66. PubMed ID: 12082455
[TBL] [Abstract][Full Text] [Related]
5. Effect of p53 gene transfer and cisplatin in a peritonitis carcinomatosa model with p53-deficient ovarian cancer cells.
Kigawa J; Sato S; Shimada M; Kanamori Y; Itamochi H; Terakawa N
Gynecol Oncol; 2002 Feb; 84(2):210-5. PubMed ID: 11812076
[TBL] [Abstract][Full Text] [Related]
6. Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications.
Horowitz J
Curr Opin Mol Ther; 1999 Aug; 1(4):500-9. PubMed ID: 11713766
[TBL] [Abstract][Full Text] [Related]
7. Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500.
Buller RE; Shahin MS; Horowitz JA; Runnebaum IB; Mahavni V; Petrauskas S; Kreienberg R; Karlan B; Slamon D; Pegram M
Cancer Gene Ther; 2002 Jul; 9(7):567-72. PubMed ID: 12082456
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status.
Wolf JK; Mills GB; Bazzet L; Bast RC; Roth JA; Gershenson DM
Gynecol Oncol; 1999 Nov; 75(2):261-6. PubMed ID: 10525383
[TBL] [Abstract][Full Text] [Related]
9. Adenoviral-mediated gene therapy with Ad5CMVp53 and Ad5CMVp21 in combination with standard therapies in human breast cancer cell lines.
Parker LP; Wolf JK; Price JE
Ann Clin Lab Sci; 2000 Oct; 30(4):395-405. PubMed ID: 11045764
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer.
Coukos G; Makrigiannakis A; Kang EH; Rubin SC; Albelda SM; Molnar-Kimber KL
Clin Cancer Res; 2000 Aug; 6(8):3342-53. PubMed ID: 10955822
[TBL] [Abstract][Full Text] [Related]
11. Enhanced apoptotic activity of a p53 variant in tumors resistant to wild-type p53 treatment.
Atencio IA; Avanzini JB; Johnson D; Neuteboom S; Vaillancourt MT; Nielsen LL; Hajian G; Sutjipto S; Sugarman BJ; Philopena J; McAllister DL; Beltran JC; Nodelman M; Ramachandra M; Wills KN
Mol Ther; 2001 Jul; 4(1):5-12. PubMed ID: 11472100
[TBL] [Abstract][Full Text] [Related]
12. In vivo studies of adenovirus-mediated p53 gene therapy for cis-platinum-resistant human ovarian tumor xenografts.
Song K; Cowan KH; Sinha BK
Oncol Res; 1999; 11(3):153-9. PubMed ID: 10527075
[TBL] [Abstract][Full Text] [Related]
13. Pro-apoptotic treatment with an adenovirus encoding Bax enhances the effect of chemotherapy in ovarian cancer.
Xiang J; Gómez-Navarro J; Arafat W; Liu B; Barker SD; Alvarez RD; Siegal GP; Curiel DT
J Gene Med; 2000; 2(2):97-106. PubMed ID: 10809143
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer.
Wolf JK; Bodurka DC; Gano JB; Deavers M; Ramondetta L; Ramirez PT; Levenback C; Gershenson DM
Gynecol Oncol; 2004 Aug; 94(2):442-8. PubMed ID: 15297186
[TBL] [Abstract][Full Text] [Related]
15. p53 gene status and chemosensitivity in ovarian cancer.
Kigawa J; Sato S; Shimada M; Takahashi M; Itamochi H; Kanamori Y; Terakawa N
Hum Cell; 2001 Sep; 14(3):165-71. PubMed ID: 11774736
[TBL] [Abstract][Full Text] [Related]
16. P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome.
Gadducci A; Di Cristofano C; Zavaglia M; Giusti L; Menicagli M; Cosio S; Naccarato AG; Genazzani AR; Bevilacqua G; Cavazzana AO
Anticancer Res; 2006; 26(1B):687-93. PubMed ID: 16739339
[TBL] [Abstract][Full Text] [Related]
17. ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients.
You L; Yang CT; Jablons DM
Cancer Res; 2000 Feb; 60(4):1009-13. PubMed ID: 10706117
[TBL] [Abstract][Full Text] [Related]
18. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma.
Mujoo K; Maneval DC; Anderson SC; Gutterman JU
Oncogene; 1996 Apr; 12(8):1617-23. PubMed ID: 8622881
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo adenovirus-mediated p53 and p16 tumor suppressor therapy in ovarian cancer.
Modesitt SC; Ramirez P; Zu Z; Bodurka-Bevers D; Gershenson D; Wolf JK
Clin Cancer Res; 2001 Jun; 7(6):1765-72. PubMed ID: 11410518
[TBL] [Abstract][Full Text] [Related]
20. Adenovirus-based transfer of wild-type p53 gene increases ovarian tumor radiosensitivity.
Gallardo D; Drazan KE; McBride WH
Cancer Res; 1996 Nov; 56(21):4891-3. PubMed ID: 8895740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]